Exclusive-Eisai expects 1,500 Alzheimer’s patients in China launch, sees ‘huge’ growth By Reuters Read more
New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer’s Disease Read more